The Hollings Cancer Center Clinical Trials Office (CTO) provides a centralized office for the conduct of cancer clinical trials at the Medical University of South Carolina. The purpose of the CTO is to provide an effective and efficient infrastructure to support HCC investigators in developing, implementing and reporting on all cancer clinical research studies at MUSC.
The major functions of the CTO are to:
- Serve as a central clinical research information repository that facilitates Center-wide communications, subject accrual tracking and monitoring of the progression for all studies from inception to final publication.
- Assist HCC investigators in the timely activation, and administration of studies, including the preparations and communications required for scientific, ethical, financial and operational reviews as well as ongoing support for annual regulatory reviews.
- Assist clinicians in screening and enrolling patients for clinical research studies.
- Coordinate and ensure the completion of patient-specific study requirements.
- Provide data management support for clinical research studies.
- Prepare medical and research records for internal and external quality and compliance audits.
- Provide training and education pertaining to the best practices in conducting clinical studies to clinical and CTO staff and new investigators.
- Communicate the availability of clinical studies to HCC physicians, referring physicians and the public.
The Clinical Trials Office participates in phase I, II and III clinical trials originating from the NCI's National Clinical Trials Network, selected pharmaceutical-sponsored and investigator-initiated studies. To learn more about the site capabilities of the CTO, please contact Carolyn Britten, M.D., Associate Director of Clinical Investigations or David Marshall, M.D., Deputy Associate Director of Clinical Investigations.
If you publish a manuscript including research supported by the Clinical Trials Office, the HCC recommends the following text to be placed in the acknowledgement section: "Supported in part by the Clinical Trials Office, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313)."